Pharnext

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Pharnext strengthens its ties with Néovacs to secure the next steps in its development

The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company

Pharnext: completion of the reverse split of its shares on the basis of 1 new share for 5,000 old shares, start of trading of the shares resulting from the reverse split, and capital reductions

Hugo Brugière Joins Pharnext Board of Directors

Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th,

Pharnext Reports First Half 2022 Financial Results

Pharnext announces a reverse stock split and suspension of the right to exercise all the securities giving access to Pharnext’s share capital including the conversions of convertible bonds

Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A

Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia

Pharnext: Findings From ‘Real-World’ Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease

Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial

Pharnext Appoints Dr. Rob Quinn as Chief Financial Officer

Pharnext Announces a €2.5m Loan Agreement with Néovacs

Pharnext Appoints Antoine Gravelle as General Counsel

Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022

Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors

Pharnext Announces Successful Debt Refinancing and New Loan Agreement

Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A

Pharnext: Tirage d’une onzième tranche de 300 obligations convertibles en actions

Pharnext annonce la tenue de son assemblée générale annuelle mixte le 17 juin 2022 et une réduction de capital motivée par des pertes

Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting

Pharnext: Tirage d’une dixième tranche de 300 obligations convertibles en actions

Pharnext: Pharnext Reports Full Year 2021 Financial Results and Recent Business Updates

Pharnext: Tirage d’une neuvième tranche de 300 obligations convertibles en actions

Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors

Pharnext: Tirage d’une huitième tranche de 300 obligations convertibles en actions

Pharnext: Assemblée Générale Extraordinaire fixée au 21 mars 2022

Pharnext: Report de l’assemblée générale extraordinaire des actionnaires du 28 février 2022

Pharnext appoints Valérie Worrall as Chief Financial Officer